Business Wire

Data Presented at the Miami Breast Cancer Conference Show MammaPrint ® and BluePrint ® Accurately Predict Pathologic Complete Response Rate Regardless of Age

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint® and BluePrint®, and underpin both assays’ pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38th Annual Miami Breast Cancer Conference.

The poster, entitled Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients,outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patients of all subtypes, regardless of age. This analysis reinforces both tests’ use to better tailor pre-operative treatment and in determining the best timing for surgery for patients of all ages with breast cancer.

“Among the many clinically meaningful findings provided by the NBRST trial, we were focused on the importance of conducting a further sub-analysis of the trial’s data based on age,” said William Audeh, MD, Chief Medical Officer of Agendia and a study author. “It is critical that we have a full understanding of the biology of each patient’s breast cancer, and whether age in itself affects the response to chemotherapy in the neoadjuvant setting. Our findings indicate that it is the genomic profile of the tumor, and not age of the patient, which determines response to chemotherapy. It is useful, in these challenging times, to know that we can triage each patient effectively with genomic tools that can give predictive and prognostic information essential for optimal treatment planning.”

This age-based analysis reinforces the importance of the multi-disciplinary care team having meaningful genomic information at the earliest point after a diagnosis of breast cancer to inform the decision for the timing of surgery and systemic therapy. With recent analyses of pre-menopausal patients with breast cancer suggesting a clinical benefit to adjuvant chemotherapy, genomic tests that accurately predict outcomes across age ranges are crucial in the research community’s ongoing efforts to determine whether this age-dependent benefit is due to a direct cytotoxic effect on the tumor or a secondary hormonal effect due to ovarian suppression by chemotherapy.

“These data confirm that genomic tests, like MammaPrint and BluePrint, have a place in every breast cancer diagnosis,” said James Pellicane, MD, Director of Breast Oncology at the Bon Secours Cancer Institute and an author of the poster. “Diving into the large bank of knowledge provided by the NBRST trial continues to help us facilitate more informed treatment decisions that will benefit the enormously diverse group of people who are diagnosed with breast cancer.”

Agendia’s mission is to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey, which the company prioritizes by continuing to look deeper into the arsenal of data that will help treat cancer.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

Contact information

Media

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MapleStory Celebrates Its 16th Anniversary With Hotel Update and Maple Memories21.4.2021 20:00:00 CEST | Press release

MapleStory, the iconic free-to-play global MMORPG from Nexon, is opening the doors to the exclusive Hotel Maple to celebrate the game’s 16th anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005069/en/ MapleStory Celebrates Its 16th Anniversary With Hotel Update and Maple Memories (Graphic: Business Wire) Starting today, players can enjoy the benefits of the Hotel Maple VIP Membership and participate in special anniversary events including new missions and mini-games, and can take to social media to reconnect with old gaming friends and share their most memorable MapleStory moments. Maplers with characters at level 101 or higher can gain access to the VIP Membership at Hotel Maple, which is a special reward-earning ranking system for the 16th anniversary. Knowledgeable Hotel Maple concierges are available on site to explain the many benefits of the VIP Membership and assist players every step of the way to ma

RoboSense LiDAR Partners with Banma and AutoX on High-Level Autonomous Driving Platform21.4.2021 20:00:00 CEST | Press release

RoboSense (https://www.robosense.ai/), the leading smart LiDAR sensor provider announced a strategic partnership with Banma Network Technology, an intelligent automobile operating system and solution provider that cooperated with Alibaba Group and SAIC Motor, and AutoX, China's most advanced self-driving AI platform, to build a high-level autonomous driving platform for intelligent vehicles through in-depth cooperation in the 3D LiDAR sensor, AI algorithm, and intelligent automobile operating system, and create an advanced smart cockpit based on human-machine co-driving. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005523/en/ (Photo: Business Wire) The cooperation will promote the integration of smart cockpits with autonomous driving systems through the fusion of hardware, software, and AI capabilities. RoboSense will provide the robust LiDAR sensor solution that not only meets the need for high-level autonomous driv

ISACA Offers New Certification for Upskilling and Cross-skilling in Emerging Technologies21.4.2021 15:35:00 CEST | Press release

Emerging technologies are essential to digital transformation and business progress—whether it is blockchain used in supply chains and in the financial industry or artificial intelligence in driving efficiency across sectors. IT professionals seeking to boost their skillset in emerging technologies and ensure their knowledge is up to date can now pursue the Certified in Emerging Technology (CET) certification from global IT professional association and learning organization ISACA. Established IT professionals, students and recent grads alike can set themselves apart with employers and gain foundational knowledge about the Internet of Things (IoT), artificial intelligence (AI), blockchain and cloud without having prior experience. Along with the recently launched ISACA credential, the Information Technology Certified Associate (ITCA), the CET certification is unique in offering a vendor-agnostic, hybrid learning model. The CET model features both performance-based and knowledge-based le

BORN and Alkeon Bolster Leadership Team with the Appointment of Stewart Mancey as Director of E-Concession & Retail Partners21.4.2021 15:12:00 CEST | Press release

Total global e-commerce sales represent over $25 trillion in value today, with B2B e-commerce global merchandise value representing more than $12 trillion (Statista). With close to 2 billion websites online as of January 2021, the process of navigating products and determining quality sources can be an arduous, time-consuming, and sometimes impossible task. With billions of individual products and brands represented online and the number of products only increasing by the minute, the importance of curation becomes a critical expertise to support digital transactions. Layer in the changing ways consumers make purchase decisions, including assessing sustainability, integrity, and purpose, and the importance of product strategy is perhaps more vital than ever. The product curation process creates bespoke collections that appeal to specific demographics and niche customer groups. Modern product curation leverages customer segmentation data and purchase behavior information, followed by per

Mavenir Announces $500 Million Private Placement with Koch Strategic Platforms21.4.2021 15:00:00 CEST | Press release

Koch Strategic Platforms (“KSP”), a subsidiary of Koch Investments Group, announced today it has signed an agreement for a strategic minority equity investment in Mavenir (the “Company”). Affiliates of Siris Capital Group, LLC (“Siris”), a leading technology focused private equity firm, will remain majority equity holders. Mavenir is the only U.S. based provider of end-to-end, cloud-native software to meet the growing demand for 5G digital transformation by communication service providers (“CSPs”) and enterprises. KSP, which focuses on growth equity through four thematic sectors—computing and connectivity, industrial automation, energy transformation, and health care—is a natural partner for Mavenir’s 5G transformational efforts. KSP aims to be a partner beyond capital investment by leveraging the resources and capabilities of Koch Industries to accelerate growth for companies in which it invests, as well as identifying new platforms for Koch. “We have built a next-generation software

Technology Innovation Institute’s Secure Systems Research Centre Partners with World-leading Universities across Groundbreaking Projects21.4.2021 14:45:00 CEST | Press release

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Khalifa University, Georgia Institute of Technology, Tampere University and University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Secure Systems Research Centre also recently announced that it had partnered with Purdue University. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005624/en/ Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) (Photo: AETOSWire) The announcement of these collaborations is the latest in a series of announcements by Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020. Secure Systems Research Centre is one of the initial seven dedicated research

Deel, the Leading Platform for Global Hiring and Payments, Raises $156m Reaching Unicorn Status21.4.2021 14:07:00 CEST | Press release

Deel, the international payroll company shattering hiring barriers worldwide, announced today that it has raised $156 million in Series C funding led by the YC Continuity Fund and has welcomed Ali Rowghani to its board. The round was co-led by existing investors Andreessen Horowitz and Spark Capital. Dara Khosrowshahi, Lachy Groom, Jeffrey Katzenberg, Jeff Wilke, and Anthony Schiller also participated in the round, among others. With a valuation of $1.25 billion, Deel has emerged as a market leader in the global payroll and compliance space. Deel allows businesses to hire anyone, anywhere, in a compliant manner. Hiring and onboarding international employees or contractors takes under 5 minutes, with no local entity required. Paying them in 120+ currencies takes just a click. Deel was co-founded in 2018 by MIT alumni Alex Bouaziz and Shuo Wang. Deel was already focused on this pain point when the pandemic hit, putting the startup in a prime position to help companies adjust to the drama

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom